Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 13.35 |
| Open | 13.35 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 3200 |
| Day's range | 13.17 - 13.40 |
| 52-week range | 13.17 - 19.97 |
| Volume | |
| Avg. volume | 2,510,654 |
| Market cap | 41.825B |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | 9.95 |
| EPS (TTM) | 1.32 |
| Earnings date | N/A |
| Forward dividend & yield | 0.84 (6.36%) |
| Ex-dividend date | 30 Mar 2021 |
| 1y target est | 19.13 |
- Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy as a Hedge Against Inflation
Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.
- Business Wire
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
CAMBRIDGE, Mass., November 30, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program gra
- Zacks
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.
